Transduction of 11 pancreatic cancer cell lines with a replication-deficient adenovirus 5 expressing enhanced green fluorescent protein (Ad5EGFP) was analyzed and variable EGFP levels were observed, ranging from o1% to B40% of cells transduced, depending on the cell line. Efficient Ad5EGFP transduction was associated mainly with higher levels of cell surface Coxsackie and adenovirus receptor (CAR) but not with expression of a v b 3 and a v b 5 integrins and was fiber dependent. Reduction of CAR by RNA interference resulted in a corresponding decrease in Ad5EGFP transduction. Pre-treatment of Ad5EGFP with blood coagulation Factor X increased virus entry even in the presence of low CAR levels generated by RNA interference, suggesting a potential alternative route of Ad5 entry into pancreatic cancer cells. Immunohistochemistry carried out on 188 pancreatic ductal adenocarcinomas and 68 matched controls showed that CAR was absent in 102 (54%) of adenocarcinomas, whereas moderate and strong staining was observed in 58 (31%) and 28 (15%) cases, respectively. Weak or absent CAR immunolabeling correlated with poor histological differentiation of pancreatic cancer. In normal tissue, strong immunolabeling was detected in islet cells and in the majority of inter-and intralobular pancreatic ducts.
Introduction
Pancreatic cancer is a major leading cause of cancer death in the Western world, with B40 000 deaths per year occurring in Europe and around 26 000 deaths in the United States of America each year. In addition, the incidence of this cancer has been steadily increasing over the past 20 years, and it is now the fourth most common cause of cancer deaths. 1 Fatality is because of the lack of effective screening strategies, inconspicuous early symptoms and poor response to existing therapies leading to a median survival of B1 year. 2 New forms of treatment for this disease are urgently needed, and this has led to research on the use of human viruses as therapeutic gene delivery systems for the treatment of pancreatic cancers. 3 Human adenoviruses (Ad), especially those of species C such as Ad5, have considerable potential as gene therapy vectors due to many favorable features, for example, their ability to grow to high titers in complementing cell lines, such as 293 cells, and their efficient transduction of a wide variety of target tissues. 3 Despite certain adverse reports, they are considered to be relatively safe to be used as vectors for gene transfer in humans. 3 Species C Ad infection is initiated by attachment of the knob domain of the virus fiber protein to the human Coxsackie B and adenovirus receptor (CAR) on the cell surface and a further interaction between the Arg-Gly-Asp motif of the penton base with a v b 3 and a v b 5 integrins, which allows internalization of virus into the cell by receptor-mediated endocytosis. 4 Following internalization, the virus is localized within cellular vesicles, initially in clathrincoated vesicles and then in endosomes. The virus escapes from the endosome, and the partially disassembled virus translocates to the nuclear pore complex and releases its genome into the nucleoplasm where subsequent steps of viral replication take place. 5 The virus replication cycle is completed by cell death and release of progeny viruses.
The susceptibility of cells to infection by Ad5 depends crucially on whether they express the primary (CAR) and secondary attachment molecules (integrins). 4, 5 As CAR serves as the primary attachment molecule for most human Ads, its presence may be a limiting step for efficient adenovirus entry. Indeed, downregulation of CAR expression levels seems to be a limiting step for entry of certain Ads in a number of human primary cells or established cell lines. 5 Soluble factors present in body fluids, such as lactoferrin and blood coagulation factors, also promote Ad entry into human cells. 6 The most extensively studied of these factors is Factor X (FX), which interacts with the hexon capsomere of Ad5 and heparan sulfate proteoglycans on the surface of target cells, providing an alternative entry pathway into human cells. 7, 8 The FX pathway has been mainly studied in Hep G2 cancer cells derived from human liver, although stimulatory effects of FX on Ad5 entry into lung cancer cells have been reported. 9 In this study, a panel of 11 human pancreatic cancer cell lines was used to assess the role of CAR and integrins in Ad5 transduction. Using RNA interference, the level of cell surface CAR was experimentally reduced to levels comparable with those found on low CAR-expressing pancreatic cancer cell lines and the impact on Ad5 entry was assessed. The role of FX in stimulating Ad5 entry into pancreatic cancer cell lines was also determined. The expression of CAR in a large series of pancreatic ductal carcinomas and normal pancreatic tissues was studied by immunohistochemical analysis of tissue microarrays.
Materials and methods

Cell culture
Nine established human pancreatic cancer cell lines were studied. PSN-1 (derived from a pancreatic adenocarcinoma), MIA PaCa-2 (an undifferentiated pancreatic carcinoma), ASPC-1 (derived from a metastatic ascites from a patient with pancreatic adenocarcinoma), Panc-1 (a ductal pancreatic carcinoma), Capan-1 (derived from a liver metastasis from a patient with pancreatic adenocarcinoma) and BxPc-3 (derived from a moderate to poorly differentiated primary pancreatic adenocarcinoma) were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) or the American Type Culture Collection (ATCC). A818-4 cells were derived from an ascites, PT45 cells were from a primary pancreatic adenocarcinoma and T3M4 cells were derived from a lymph node metastasis. 10, 11 Two more recently established human pancreatic cancer cell lines, NP9 and NP18 (derived from orthotopic transplants of pancreatic carcinomas in nude mice), kindly provided by Dr R Alemany, L'Hospitalet de Llobregat, Barcelona, Spain, were also studied. 12 Human lung carcinoma cells (A549) and HeLa (cervical adenocarcinoma) cells, which are permissive for adenovirus infection and Chinese hamster ovary cells (CHO), which are non-permissive were obtained from ECACC. Human Hep G2 (hepatocellular carcinoma) cells were kindly provided by Professor M Harris, University of Leeds. All human cells were grown in Dulbecco's modified Eagle's medium (DMEM) and CHO cells were grown in minimum essential medium a medium. All media were supplemented with 1% (v/v) penicillin/streptomycin (10 000 U ml À1 each), 2% (v/v) L-glutamine (2 mM) and 10% (v/v) fetal calf serum (FCS) and the cells were maintained at 37 1C in a humidified atmosphere containing 5% CO 2 . Minimum essential medium a medium was purchased from Invitrogen Ltd (Paisley, UK), FCS was purchased from LabTech International (East Sussex, UK) and DMEM medium and supplements were from SigmaAldrich (Poole, UK).
Analysis of cell surface molecules by flow cytometry Cells were grown in T75 flasks, harvested by brief treatment with trypsin (Sigma-Aldrich) and resuspended in phosphate-buffered saline (PBS; Sigma-Aldrich). In all, 200 000 cells were incubated with 50 ml of either a 1:100 dilution of mouse monoclonal anti-a v b 3 antibody, which recognizes the assembled a v b 3 (CD51:CD61) complex (obtained from Serotec, Oxford, UK) or a 1:50 dilution of mouse monoclonal P1F6 antibody, which recognizes the assembled avb5 complex (Immunologicals Direct, Oxford, UK) or a 1:10 dilution of mouse monoclonal anti-CAR (ab9891, obtained from Abcam, Cambridge, UK) or a 1:10 dilution of rabbit anti-human CAR 13 or no primary antibody (negative control) for 30 min at 4 1C. Cells were washed with an excess of PBS and incubated with 50 ml (1:50 dilution) fluorescein isothiocyanateconjugated secondary antibody (Sigma-Aldrich) for 30 min at 4 1C before being washed again with PBS. Finally, the cells were analyzed on a FACScalibur flow cytometer using CellQuest software (Becton Dickinson, Oxford, UK).
Transduction of cells with Ad5EGFP
Ad5EGFP virus is a replication-deficient recombinant Ad5 that contains the enhanced green fluorescent protein (EGFP) gene under the control of the cytomegalovirus promoter, inserted in place of the E1 region, 14 kindly provided by Dr A Tolkovsky, University of Cambridge, UK. The virus was propagated and titrated in 293 cells, as previously described.
14 Cells (1 Â 10 5 ) were grown in six-well dishes to B80-90% confluence. They were washed twice with PBS and treated with Ad5EGFP at a multiplicity of infection of 10 focus forming unit per cell, where 1 focus forming unit is approximately equal to 300 virus particles (vp). After incubation for 1 h at 37 1C, the cells were washed twice with DMEM containing 2% (v/v) FCS and fresh DMEM containing 10% (v/v) FCS was added before the cells were incubated for a further 24 h at 37 1C. The cells were harvested and EGFP expression was assessed by flow cytometry.
In certain experiments, Ad5EGFP was pre-incubated with rabbit antibodies raised against recombinant Ad5 fiber or penton base (GEB, unpublished results) or mouse monoclonal anti-Ad5 hexon antibody (purified by protein A-sepharose affinity chromatography from culture medium derived from the 2Hx2 hybridoma, obtained from ATCC). Serum (1 ml) or purified antibody ( In certain experiments, Ad5EGFP was pre-treated with FX, as described above, before addition to cells which had been transfected with either control or CAR siRNA and incubated for 72 h at 37 1C. Transduced cells were incubated for a further 24 h at 37 1C and EGFP expression analyzed by flow cytometry.
Virus particle (vp) binding assay Cells (1 Â 10 5 ) were detached with Versene and resuspended in 100 ml binding buffer (PBS supplemented with 1% BSA, 1 mM MgCl 2 and1 mM CaCl 2 ) containing up to 10 000 vp per cell and incubated for 1 h on ice. Cells were washed in PBS, resuspended in 100 ml of binding buffer with 2 ml of rabbit polyclonal anti-fiber or anti-penton base serum or 2.5 mg mouse monoclonal anti-hexon antibody and incubated for 30 min on ice. The cells were washed, resuspended in 100 ml Alexa 488-labelled goat anti-mouse or anti-rabbit immunoglobulins (Invitrogen; diluted 1:400 in binding buffer), incubated for 30 min on ice, washed in PBS and analyzed by flow cytometry.
Human tissue samples
Formalin-fixed, paraffin-embedded tissue blocks of normal pancreatic parenchyma from patients who underwent resection for trauma or pancreas-unrelated disease, were retrieved from the archive of St James's University Hospital, Leeds. In addition, 188 cases of pancreatic ductal adenocarcinoma, each represented by three tissue cores, and 68 matched controls of normal pancreatic tissue, were included in a tissue microarray. The mean patient age was 64.4 years (range: 36-81). In all, 98 patients (52%) were male. The pathological stage according to the International Union against Cancer Tumor Node Metastasis staging system 15 was as follows: pT3: n ¼ 181, pT2: n ¼ 7, pN1: n ¼ 176, pN0: n ¼ 12. Of all ductal adenocarcinomas, 137 (73%) were well or moderately differentiated, whereas 51 cancers (27%) were of poor differentiation.
Immunohistochemistry CAR protein expression was detected by immunostaining of 3 mm formalin-fixed paraffin-embedded tissue sections. Antigen retrieval was performed as described previously. 16 In brief, sections were incubated in 1 mM EDTA pH 8.0/0.1% Tween 20 on a hot plate stirrer at 65 1C for 16 h. Sections were then cooled down to room temperature in tap water and, following a wash in Trisbuffered saline pH 7.6 (TBS), they were incubated with rabbit anti-human CAR antibody 13 (diluted 1:200 in TBS) for 1 h at room temperature. After washing in TBS, sections were incubated with Envision reagent (Dako Real Envision K5007, Ely, UK) for 30 min at room temperature. After a further TBS wash, DAB chromogen (Dako Real DAB plus K5001) was applied for 5 min. Following a final TBS wash, sections were counterstained in Mayer's Haematoxylin and mounted. Sections of normal prostatic tissue were used as a positive control. Omission of the primary antibody was used as a negative control. Immunostaining results were scored according to a four-tier system: 0, absence of staining; 1, weak and/or focal staining; 2, moderate staining in majority of cancer cells; 3, strong staining in majority of cancer cells.
Statistical analysis
Flow cytometric data were expressed as means ± s.e.m. and were the result of at least three independent biological replicates. In immunohistochemical analysis, differences between groups were analyzed by the w 2 -test; a P-value of o0.05 was considered significant.
Results
Transduction of pancreatic cancer cell lines by recombinant Ad5EGFP
The recombinant Ad5EGFP virus was used to examine the susceptibility of 11 pancreatic cancer cell lines to adenovirus 5 (Ad5) transduction. As transduced cells can be directly measured by the presence of the EGFP transgene, this enables the determination of gene transfer efficiency without selection or antibody staining. Conversely, cells resistant to Ad5EGFP transduction will not express the EGFP transgene product. The CHO cell line has been previously described as being resistant to adenovirus infection and was used as a negative control. 13, 17 The A549 cell line is a CAR-positive human lung carcinoma cell line that is highly susceptible to Ad5 infection and was used as a positive control. A summary of the results of five independent analyses in Figure 1a showed that certain pancreatic cancer cell lines were susceptible to adenovirus transduction, whereas others were very weakly transduced. Using an amount of Ad5EGFP that was sufficient to transduce 470% of A549 cells, transduction efficiencies of the pancreatic cancer cell lines ranged from o1% to B40% of cells transduced. The PSN-1, BxPc-3 and NP9 cell lines showed very low levels of transduction by Ad5EGFP (o4% transduced cells). In contrast, the A818-4 cell line was most susceptible to transduction with Ad5EGFP (B40% transduced cells), followed by Panc-1, NP18 and MIAPaCa-2. The negative control cell line CHO exhibited negligible transduction. The low levels of EGFP expression in Ad5EGFP-transduced pancreatic cancer cells could have been because of the impaired binding of virus at the cell surface. This was, therefore, investigated by determining the levels of cell surface attachment molecules for Ad5 (namely CAR and a v integrins) in the pancreatic cancer cell lines.
Expression of the CAR in pancreatic cancer cell lines Cell lines were analyzed for cell surface expression of CAR by flow cytometry. Preliminary experiments were performed to ensure that a saturating level of polyclonal rabbit anti-human CAR antibody was used in all experiments (data not shown). Flow cytometric analysis of cell surface CAR expression (Figure 1b) Reduction of cell surface CAR by RNA interference and the impact on Ad5 transduction of pancreatic cancer cells The level of cell surface CAR on pancreatic cancer cells was reduced by RNA interference to determine whether there was a corresponding reduction in Ad5EGFP transduction ( Figure 3 ). HeLa cells were chosen as a control cell line, which can both be efficiently transfected with siRNA and supports Ad5EGFP entry. An approximate 60% reduction of cell surface CAR following siRNA treatment was obtained in HeLa cells and Ad5EGFP transduction was correspondingly reduced by B50% (Figure 3) . Two pancreatic cancer cell lines, Panc-1 and A818-4, were chosen for analysis, as they expressed relatively high levels of CAR and were readily transduced by Ad5EGFP (Figure 1 ). In Panc-1 cells, cell surface CAR was reduced by B80%, whereas Ad5EGFP transduction was reduced by around 65% and in A818-4 cells, lower levels of siRNA-mediated reduction of CAR were achieved of around 50% of control siRNA-treated ). Therefore, the role of FX in entry of Ad5EGFP into pancreatic cancer cells expressing relatively high or low levels of CAR (A818-4 and BxPc-3, respectively) was examined to determine whether FX might provide a non-CAR-dependent route of Ad5 entry into pancreatic cancer cells. A818-4 and BxPc-3 pancreatic cancer cells were chosen for analysis, as they exhibited high and low levels of transduction by Ad5EGFP, respectively (Figure 1a ). Hep G2 cells (which were derived from a liver cancer and were used to identify the enhancing effect of FX on Ad5 entry 7, 8 ) and HeLa cells were used as controls. Hep G2 cells expressed relatively low levels of CAR, of a similar order to BxPc-3 cells (Supplementary Figure 1) .
To ablate the interaction of Ad5EGFP with cell surface CAR and integrins so that non-CAR-mediated entry could be studied, polyclonal rabbit antibodies against fiber or penton base were bound to vp before being treated with physiological concentrations (1 IU ml Pre-treatment of Ad5EGFP with FX resulted in an approximate twofold stimulation of EGFP expression in Hep G2 and HeLa cells and a four-fold stimulation in pancreatic BxPc-3 cells, although the effect of FX treatment on transduction of A818-4 cells was less marked (Figure 4a ). FX treatment of Ad5EGFP (to which antifiber antibodies were bound) partially restored Ad5EGFP-mediated transduction of HeLa and BxPc-3 cells and almost completely restored transduction of HepG2 and A818-4 cells (Figure 4a) . The presence of anti-penton base antibodies bound to Ad5EGFP did not alter the stimulation of transduction due to FX (Figure 4b) .
FX pre-treatment of Ad5EGFP was able to completely restore transduction of A818-4 cells in which CAR had been reduced by B50% by RNA interference. Transduction of CAR siRNA-treated Hep G2 and HeLa cells was restored to B75 to 80% of control levels by FX (Figure 4c ).
CAR expression in the normal pancreas and in pancreatic cancers
As the pancreatic cancer cell lines have been maintained in culture for long periods of time, it was important to relate CAR levels in cultured cells to those found in normal and pancreatic cancer tissue. To establish the immunohistochemical detection of CAR, normal prostatic tissue was used as a positive control and in accordance with a previous study, 18 immunostaining for CAR showed strong membranous labeling of the lateral and apical borders of the glandular epithelium as well as cytoplasmic staining of basal cells in hyperplastic glands (Figures 5a and b) . In normal pancreatic tissue, the vast majority of islet cells showed strong staining, which was mainly cytoplasmic and, in some cells, also of a membranous distribution pattern (Figure 5d ). CAR immunostaining was present in columnar epithelium lining the entire pancreatic duct system, from the main pancreatic to the most peripheral ramifications of the intralobular ducts. Staining of the ductal epithelium occurred mainly at the luminal cell membrane, although labeling of the lateral cell borders was also seen in incidental foci of low-grade pancreatic intra-epithelial neoplasia (Figures 5e-g ). In some foci, CAR labeling of duct epithelium showed a diffuse cytoplasmic pattern. CAR immunostaining was absent in all acinar cells (Figures 5c and d) . Similar observations were made in the matched normal control samples contained in the tissue microarray. Of the 188 ductal adenocarcinomas, 58 (31%) and 28 (15%) cancers exhibited moderate and strong CAR staining, respectively. CAR labeling was weak or absent in 102 of the cases (54%; Figures 5h-k) . Immunolabelling was predominantly of a diffuse cytoplasmic pattern, whereas a small number of cases showed staining of the apical or lateral cell membrane (Figures 5l-n) . Of 137 moderately and well-differentiated adenocarcinomas, 74 cancers (54%) exhibited moderate or strong CAR staining, whereas in 63 (46%) cancers, CAR immunolabelling was weak or absent. In contrast, only 1 of 51 (2%) poorly differentiated ductal adenocarcinomas was strongly positive, whereas staining was of moderate intensity in 11 (22%) cancers and weak or absent in 39 (76%) cases (P ¼ 0.0001). There was no correlation between the subcellular localization of CAR and tumor differentiation.
Discussion
Investigations into the susceptibility of 11 established pancreatic cancer cell lines (including two more recently established cell lines NP9 and NP18 12 ) to Ad5EGFP demonstrated a wide range of transduction efficiency with almost half of the pancreatic cancer cell lines studied being poorly transduced (Figure 1 ). The most highly transduced pancreatic cell lines (A818-4 and Panc-1) showed B50% of the transduction of control A549 cells. It is also of interest to note that, of the two more recently established cancer cell lines used in this study (NP9 and NP18), NP9 was refractory to adenovirus transduction to the same extent as several of the established, highly passaged pancreatic cancer cell lines, but this was not the case for NP18 cells. There is considerable variation in the published data relating to Ad5 transduction of pancreatic cancer cell lines; [19] [20] [21] this study broadens knowledge of Ad5-mediated gene transfer to pancreatic cancer cells by examining a much larger number of cell lines. Other investigations have also shown a wide diversity of susceptibility to Ad5-mediated transduction with several cancer and established cell lines showing negligible transduction. 17, [20] [21] [22] [23] The complete loss of CAR expression at the level of transcription has been reported in human bladder and cervical cancer cell lines. 24, 25 Here cell surface CAR was detected in all of the pancreatic cancer cell lines but varied in its level of expression (Figure 1 ). However, although there was no obvious quantitative correlation between the efficiency of transduction and the level of cell surface CAR, cells with the highest level of cell surface CAR (with the exception of the T3M4 cell line) were most efficiently transduced, whereas cells with the lowest levels of CAR were poorly transduced (Figure 1 ). This might suggest that there is a threshold level of cell surface CAR above which there is a discernible effect on Ad5 transduction. This is in broad agreement with certain studies on a range of human cancer cell lines. 17, [24] [25] [26] [27] In some reports, although there was no correlation between expression of Ad attachment molecules and efficiency of transduction, the use of specific antibodies against these molecules (that is, CAR and integrins) led to a reduction in transduction. 20 No correlation was observed between transduction and expression of either the a v b 3 or a v b 5 integrin (Figures 1a  and 2a and b) . Previous investigations on the relative importance of cell surface attachment molecules have shown that CAR expression appears to regulate cell susceptibility to Ad5 transduction much more significantly than a v -integrin expression in a wide range of primary cells and established cell lines. [28] [29] [30] [31] [32] However, another report has suggested that transgene expression in Ad5-transduced lung and pancreatic cancer cell lines correlated with levels of b 3 integrin. 20 Furthermore, it has recently been proposed that when cell surface CAR levels are low, a v b 5 can function as an attachment molecule for Ad5 in melanoma and breast cancer cell lines. 33 Results presented here show that experimental reduction of cell surface CAR by RNA interference in the Panc-1 cell line (which expressed relatively high levels of CAR and both integrins a v b 3 and a v b 5 ; Figures 1b and 2 ) led to a corresponding reduction in transduction by Ad5EGFP. Using a similar approach with another relatively high CAR-expressing pancreatic cancer cell line, A818-4, some reduction of Ad5-mediated transduction was obtained, but not to an extent that corresponded to the magnitude of CAR reduction (Figure 3 ). In addition, when cell surface CAR expression levels were reduced in Panc-1 cells by RNA interference to a level similar to that in the low CAR-expressing BxPc-3 cell line, comparable levels of Ad5EGFP transduction were observed (data not shown). Interestingly, A818-4 cells and Panc-1 cells expressed appreciable levels of a v b 3 , whereas A818-4 expressed very little a v b 5 and Panc-1 expressed the highest Figure 5 CAR immunostaining in the normal pancreas and pancreatic cancer. (a) To establish the specificity of the rabbit polyclonal anti-human CAR antibody, prostate tissues were initially used, as they had previously been extensively studied. 18 Normal prostatic glands showed strong membranous labeling of the lateral and apical borders of the columnar epithelium ( Â 630). (b) In hyperplastic prostatic glands, basal cells exhibited cytoplasmic immunolabelling ( Â 720). (c, d) CAR immunostaining in normal pancreatic parenchyma. Immunolabelling was present in small intralobular ducts and absent in acinar cells (c; Â 400). Islet cells were strongly positive (d; Â 400). (e-g) CAR immunostaining in normal pancreatic ducts. The main pancreatic duct (e; Â 400) and branch ducts (f; Â 630) exhibited membranous staining of the apical cell border, whereas labeling of the lateral epithelial cell borders was seen in incidental pancreatic intra-epithelial neoplasia-1B lesions (g; Â 400). (h-k) CAR immunostaining in ductal adenocarcinoma of the pancreas. Staining intensity varied from strong (h, moderately differentiated; Â 400), to moderate (j, moderately differentiated; Â 400) and weak (i, poorly differentiated; Â 630). CAR immunostaining was absent in some cancers (k, well differentiated; Â 400). (l-n) Intracellular distribution of CAR immunostaining in pancreatic cancer. Most cancers showed diffuse cytoplasmic CAR labeling (l, moderately differentiated; Â 630), whereas staining of the apical or lateral cell membrane was present in a small proportion of cancers (m, well differentiated; n, poorly differentiated; Â 720). levels of this molecule (Figure 2) . A comprehensive analysis of more pancreatic cancer lines is clearly desirable, but a conclusion from these RNA interference studies is that CAR has a major role in Ad5 transduction of pancreatic cancer cell lines but contributions of a v b 3 and other cell surface molecules cannot be excluded.
The interaction of the Ad5 fiber protein with CAR was shown to be critical for Ad5EGFP transduction of cultured pancreatic cancer cells, as disruption of this interaction with anti-fiber antibodies led to a diminished level of EGFP expression in HeLa, pancreatic (A818-4 or BxPc-3) or liver (Hep G2) cancer cells (Figure 4a) . Interestingly, although anti-penton base polyclonal antibodies interacted with Ad5 bound to HeLa cells (Supplementary Figure 2) , they did not reduce Ad5 transduction in any of the cancer cell lines tested (Figure 4b ). This might suggest that the penton-integrin interaction has a lesser role in Ad5 entry into pancreatic (and other) cancer cells than the fiber-CAR interaction. However, antibody interaction with the conserved ArgGly-Asp motifs of the closely-related Ad2 penton base has been found to be complex, with only Fab antibody fragments (and not whole immunoglobulins, as used in this study) being able to block Ad2 entry. 34 Further studies with antibody fragments recognizing penton base are necessary to clarify the role of this protein in Ad5 entry.
Recent studies have suggested that the interaction of the hexon capsomere of species C Ads (such as Ad5) with blood coagulation FX provides an alternative route of cell entry to that initiated by the fiber-CAR interaction. [5] [6] [7] [8] Initial studies focussed on a liver cancer cell line, Hep G2, but more recent studies have shown that Ad5 entry into other epithelial cancer cell lines, such as A549 and A431, is also stimulated by the presence of FX. 9, 35 Furthermore, human tumor xenografts (A549 and A431) in immunodeficient mice also showed a strong dependence on FX for their transduction by Ad5-based vectors. 35 In this study, FX was found to stimulate Ad5EGFP-mediated transduction of a low CAR-expressing pancreatic cancer cell line, BxPc-3, but such an effect was much less marked in a high CAR-expressing cell line, A818-4, suggesting a variability in response of different pancreatic cancer cells to FX (Figure 4a ). However in A818-4 cells, in which cell surface CAR had been lowered by RNA interference, FX treatment led to substantial recovery of Ad5EGFP-mediated transduction, suggesting that the presence of FX might compensate for low CAR levels to permit Ad5 entry (Figure 4c ). Treatment of A818-4 and BxPc-3 cells with FX when the fiber-CAR interaction had been inhibited by anti-fiber antibodies had a similar effect, leading to substantial recovery of Ad5EGFP-mediated transduction (Figure 4a ). Overall, FX seems to have the capacity to provide an alternative route of Ad5 entry into pancreatic cancer cell lines in culture. It remains to be established whether FX fulfils a similar role in the intact pancreas.
To address the question of the relevance of CAR expression to Ad5 transduction of pancreatic cancers in potential therapeutic applications in patients, CAR expression was analyzed by immunohistochemistry in normal and pancreatic cancer tissues ( Figure 5 ). This revealed constitutive CAR expression in normal pancreatic tissue confined to the duct lining epithelium and islets of Langerhans. These findings are interesting in the light of a study of Coxsackievirus B virus infection of pancreatic tissue in patients with fulminant viral infection or type I diabetes mellitus. 36 Coxsackievirus B virus was detected exclusively in islet cells and pancreatic duct epithelia and this distribution pattern mirrors the CAR expression pattern observed in this study.
The subcellular localization of CAR varied in both normal pancreas and pancreatic cancer tissue. Membranous expression was found frequently, but not exclusively, in normal tissue, whereas cancer cells showed predominantly cytoplasmic staining. Although similar variation of subcellular distribution of CAR has been observed in other tissues and cancers, 37, 38 the reasons and implications of this remain unclear. One possibility is that posttranslational modification of CAR by palmitoylation may regulate its intracellular distribution. 39 Only 46% of human pancreatic adenocarcinomas in this series exhibited moderate or strong CAR expression. A low level of CAR expression in pancreatic cancer has also been observed in a much smaller study of 16 cases. 40 In our study, loss of CAR expression was observed significantly more frequently in poorly differentiated cancers than in moderately and well differentiated cancers (P ¼ 0.0001). A similar correlation between the histological grade of cancer differentiation and CAR expression has been described in other human cancers, including prostate and urinary bladder cancers. 18, 41 It has been hypothesized that reduced CAR expression may cause loss of cancer cell cohesiveness and development of a more aggressive invasive phenotype.
The observations reported here are also in agreement with those of the Human Protein Atlas (http://www. proteinatlas.org/index.php) regarding the cytoplasmic/ membranous immunostaining pattern for CAR, the variability in extent and intensity of immunostaining between individual cancer cases, and the positive labeling of normal pancreatic islet cells. However, our study provides much more detailed information regarding the subcellular localization (exclusive membranous staining in some normal and neoplastic epithelial cells), the association of CAR immunostaining with the grade of tumor differentiation, the expression in normal pancreatic ductal epithelium (the presumed cellular origin of pancreatic ductal adenocarcinoma), and the positive staining in pancreatic intra-epithelial neoplasia lesions. Although in our study 15% of pancreatic cancers showed strong immunolabeling for CAR and normal acinar cells remained negative, none of the tumors described in the Human Protein Atlas were found to be strongly positive and acinar cells stained weakly in the three samples of normal pancreas.
In summary, studies presented here suggest that the reduction or loss of CAR expression is likely to be frequent in pancreatic cancers; therefore if therapeutic vectors based on Ad5 are applied to the pancreas, the status of CAR expression in the cancer needs to be evaluated. Further approaches adopted need to take account of CAR expression in the cancer and might also benefit from modification of the adenovirus fiber. For example, peptide ligands that may interact with receptors on the surface of pancreatic cancer cells have been inserted into the fiber. 19, 42 Fibers derived from species B adenoviruses (such as Ad16 and 50) that recognize CD46 (rather than CAR) may offer improved transduction of pancreatic cancer cells compared with adenoviruses containing the Ad5 fiber. 43 Engineering overexpression of CAR in target cells that are physiologically CARnegative may improve their transduction. 44 Finally, the biodistribution of adenovirus vectors in the pancreas of the intact host requires further study. A recent study of mouse organs following intravenous administration of wild-type Ad5 has shown that the pancreas is targeted by Ad5 but levels of uptake are much lower than in liver, spleen or lung tissues, 45 suggesting that improvements to targeting of adenoviruses to the pancreas are needed for effective treatment of pancreatic cancer.
